Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease

Kidney International

Volumn 64, Issue 3, 2003, Pages 978-991

  Himmelfarb, Jonathan ^a   Kane, Jane ^b   McMonagle, Ellen ^b   Zaltas, Eric ^b   Bobzin, Steve ^b   Boddupalli, Sekhar ^b   Phinney, Stephen ^b   Miller, Guy ^b  

^a MAINE MEDICAL CENTER   (United States)

^b NONE

Author keywords

CEHC; CRP; ESRD; Oxidative stress; Tocopherol

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CARBOXYETHYLHYDROXYCHROMAN; CHROMAN DERIVATIVE; GAMMA TOCOPHEROL; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE KIDNEY FUNCTION RELATION; DRUG METABOLISM; FEMALE; HEMODIALYSIS; HUMAN; HYDROPHILICITY; KIDNEY FAILURE; MALE; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; UREMIA; VITAMIN BLOOD LEVEL; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

EID: 0042932739     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00151.x     Document Type: Article

References (65)

1. HIMMELFARB J, MCMONAGLE E, MCMENAMIN E: Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 58:2571-2578, 2000
2. PERNA AF, CASTALDO P, DE SANTO NG, et al: Plasma proteins containing damaged L-isoaspartyl residues are increased in uremia: Implications for mechanism. Kidney Int 59:2299-2308, 2001
3. HIMMELFARB J, MCMONAGLE E: Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 60:358-363, 2001
4. HANDELMAN GJ, WALTER MF, ADHIKARLA R, et al: Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 51:1960-1966, 2001
5. IKIZLER TA, MORROW JD, ROBERTS LJ, et al: Plasma F2 isoprostane levels are elevated in chronic hemodialysis patients [accepted for publication]. Clin Nephrol 2002
6. HIMMELFARB J, MCMENAMIN E, LOSETO G, et al: Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Rad Biol Med 31:1163-1169, 2001
7. HIMMELFARB J, MCMONAGLE E: Manifestations of oxidant stress in uremia. Blood Purif 19:200-205, 2001
8. WITKO-SARSAT V, FREIDLANDER M, CAPEILLERE-BLANDIN C, et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-1313, 1996
9. HASSELWANDER O, YOUNG IS: Oxidative stress in chronic renal failure. Free Rad Res 29:1-11, 1998
10. GALLI F, CANESTRARI F, BELLOMO G: Physiopathology of the oxidative stress and its implications in uremia and dialysis. Cont Nephrol 127:1-31, 1999
11. SCHETTLER V, WEILAND E, METHE H, et al: Oxidative stress during dialysis: Effect on free radical scavenging enzyme (FRSE) activities and glutathione (GSH) concentration in granulocytes. Nephrol Dial Transplant 13:2588-2593, 1998
12. TETTA C, BIASIOLI S, SCHIAVON R, et al: An overview of haemodialysis and oxidative stress. Blood Purif 17:118-126, 1999
13. STENVINKEL P, HOLMBERG I, HEIMBURGER O, et al: A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure: Evidence of increased oxidative stress in malnourished patients. Nephrol Dial Transplant 13:2594-2600, 1998
14. LOUGHREY CM, YOUNG IS, LIGHTBODY JH, et al: Oxidative stress in haemodialysis. Q J Med 87:679-683, 1994
15. ROSELAAR SE, NAZHAT JB, WINYARD PG, et al: Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 48:199-206, 1995
16. BECKER BN, HIMMELFARB J, HENRICH WL, et al: Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 8:475-486, 1997
17. ANDERTON JG, THOMAS TH, WILKINSON R: Increased susceptibility to membrane lipid peroxidation in renal failure. Nephron 74:373-377, 1996
18. MAGGI E, BELLAZZI R, FALASCHI F, et al: Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 45:876-883, 1994
19. HIMMELFARB J, STENVINKEL P, IKIZLER TA, HAKIM RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524-1538, 2002
20. BOAZ M, SMETANA S, WEINSTEIN T, et al: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 356:1213-1218, 2000
21. IUPAC-IUB JOINT COMMISSION ON BIOCHEMICAL NOMENCLATURE: Nomenclature of tocopherols and related compounds: Recommendations. Eur J Biochem 123:473-475, 1981
22. BRIGELIUS-FLOHE R, TRABER MG: Vitamin E: Function and metabolism. FASEB J 13:1145-1155, 1999
23. JIANG Q, ELSON-SCHWAB I, COURTEMANCH C, et al: γ-Tocopherol and its major metabolite, in contrast to α-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci 97:11495-11499, 2000
24. AZZI A, BREYER I, FISHER M, et al: Specific cellular responses to α-tocopherol. J Nutri 130:1649-1652, 2000
25. STOCKER A, AZZI A: Tocopherol binding proteins: Their function and physiological significance. Antiox Redox Signal 2:397-404, 2000
26. TRABER MG, ARAI H: Molecular mechanism of vitamin E transport. Annual Reviews 19:343-355, 1999
27. THOMAS SR, STOCKER R: Molecular action of vitamin E on lipoprotein oxidation: Implications for atheroslerosis. Free Rad Biol Med 28:1795-1805, 2000
28. SIMON EJ, GROSS CS, MILHORAT AT: The metabolism of vitamin E. I. The absorption and excretion of d-α-tocpherol-5-methyl-C14-succinate. J Biol Chem 221:797-805, 1956
29. SIMON EJ, EISENGART A, SUNDHEIM L, et al: The metabolism of Vitamin E. II. Purification and characterization of urinary metabolites of α-tocopherol. J Biol Chem 221:807-817, 1956
30. SCHULTZ M, LEIST M, ELSNER A, et al: α-Carboxyethyl-6-hydroxychroman as a urinary metabolite of vitamin E. Methods Enzymol 282:297-310, 1997
31. SCHULTZ M, LEIST M, PETRZIKA M, et al: Novel urinary metabolite of alpha-tocopherol, 2,5,7,8-tetramethyl-2(2′-carboxyethyl)-6-hydroxychroman, as an adequate indicator of an adequate vitamin E supply? Am J Clin Nutr 62(Suppl):1527S-1534S, 1995
32. WECHTER WJ, KANTOCI D, MURRAY EDJ, et al: A new endogenous natriuretic factor: LLU-alpha. Proc Natl Acad Sci 93:6002-6007, 1996
33. EVANS HM, BISHOP KS: On the existence of a hitherto unrecognized dietary factor essential for reproduction. Science 56:650-651, 1922
34. EPSTEIN SS, FORSYTH J, SAPOROSCHETZ IB, et al: An exploratory investigation on the inhibition of selected photosensitizers by agents of varying antioxidant activity. Radiat Res 28:322-335, 1966
35. BOSCOBOINIK D, SZEWCZYK A, AZZI A: Alpha-tocopherol (vitamin E) regulates vascular smooth muscle cell proliferation and protein kinase C activity. Arch Biochem Biophys 286:264-269, 1991
36. BOSCOBOINIK D, SZEWCZYK A, HENSEY C, et al: Inhibition of cell proliferation by alpha-tocopherol: Role of protein kinase C activity. J Biol Chem 266:6188-6194, 1991
37. RIMM EB, STAMPFER MJ, ASCHERIO A, et al: Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328:1450-1456, 1993
38. STAMPFER MJ, HENNEKENS CH, MANSON JE, et al: Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 328:1444-1449, 1993
39. SALONEN JT, SALONEN R, PENTTILA I, et al: Serum fatty acids, apolipoproteins, selenium, and vitamin antioxidants and the risk of death from coronary artery disease. Am J Cardiol 56:226-231, 1985
40. KOK FJ, DE BRUIJN AM, VERMEEREN R, et al: Serum selenium, vitamin antioxidants, and cardiovascular mortality: A 9 year follow-up study in The Netherlands. Am J Clin Nutr 45:462-468, 1987
41. HENSE HW, STENDER M, BORS W, et al: Lack of an association between serum vitamin E and myocardial infarction in a population with high vitamin E levels. Atherosclerosis 103:21-28, 1993
42. OHRVALL M, SUNDLOF G, VESSBY B: Gamma, but not alpha, tocopherol levels in serum are reduced in coronary heart disease patients. J Intern Med 239:111-117, 1996
43. KRISTENSON M, ZEIDEN B, KUCINSKIENE Z, et al: Antioxidant state and mortality from coronary heart disease in Lithuanian and Swedish men: Concomitant cross sectional study of men aged 50. Br Med J 314:629-633, 1997
44. KONTUSH A, SPRANGER T, REICH A, et al: Lipophilic antioxidants in blood plasma as markers of atherosclerosis: The role of alpha-carotene and gamma-tocopherol. Atherosclerosis 144:117-122, 1999
45. ISLAM KN, O'BYRNE D, DEVARAJ S, et al: Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 150:217-224, 2000
46. ROOB JM, KHOSCHSORUR G, TIRAN A, et al: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11:539-549, 2000
47. HULTQVIST M, HEGBRANT J, NILSSON-THORELL C, et al: Plasma concentrations of vitamin C, vitamin E, and/or malondialdeyde as markers of oxygen free radical production during hemodialysis. Clin Nephrol 47:37-46, 1997
48. ROCK CL, JAHNKE MG, GORENFLO DW, et al: Racial group differences in plasma concentrations of antioxidant vitamins and carotenoids in hemodialysis patients. Am J Clin Nutr 65:844-850, 1997
49. ZIMA T, JANEBOVA M, NEMECEK K, et al: Retinol and alpha-tocopherol in hemodialysis patients. Ren Fail 20:505-512, 1998
50. LIPPA S, COLACICCO L, BONDANINI F, et al: Plasma levels of coenzyme Q(10), vitamin E, and lipids in uremic patients on conservative therapy and hemodialysis treatment: Some possible biochemical and clinical implications. Clin Chim Acta 292:81-91, 2000
51. CLERMONT G, LECOUR S, LAHET J, et al: Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: A possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res 47:618-623, 2000
52. BAKER H, HANDELMAN GJ, SHORT S, et al: Comparison of plasma α- and γ-tocopherol levels following chronic oral administration of either all-rac-α-tocopherol acetate or RRR-α-tocopherol acetate in normal adult male subjects. Am J Clin Nutr 43:382-387, 1986
53. HANDELMAN GJ, MACHLIN JJ, FITCH K, et al: Oral α-tocopherol supplements decrease plasma γ-tocopherol levels in humans. J Nutr 115:807-813, 1985
54. STAHL W, GRAF P, BRIGELIUS-FLOHE R, et al: Quantification of the alpha- and gamma-tocopherol metabolites 2,5,7, 8-trimethyl-2-(2′-carboxyethyl)-6-hydroxychroman and 2,7, 8-trimethyl-2-(2′-carboxyethyl)-6-hydroxychroman in human serum. Anal Biochem 275:254-259, 1999
55. GALLI F, LEE R, DUNSTER C, et al: Gas chromatography mass spectrometry analysis of carboxyethyl-hydrochroman metabolites of α- and γ-tocopherol in human plasma. Free Rad Biol Med 32:333-340, 2002
56. LONN EM, YUSUF S, DZAVIK V, et al: Effects of ramipril and vitamin E on atherosclerosis: A study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103:919-925, 2001
57. GIARDINI O, TACCONE-GALLUCCI M, LUBRANO R, et al: Effects of alpha-tocopherol administration on red blood cell membrane lipid peroxidation in hemodialysis patients. Clin Nephrol 21:174-177, 1984
58. ONO K: Effects of large dose vitamin E supplementation on anemia in hemodialysis patients. Nephron 40:440-445, 1985
59. YUKAWA S, HIBINO A, MAEDA T, et al: Effect of alpha-tocopherol on in vitro and in vivo metabolism of low-density lipoproteins in haemodialysis patients. Nephrol Dial Transplant 10:1-3, 1995
60. LUBRANO R, TACCONE-GALLUCCI M, MAZZARELLA V, et al: Relationship between red blood cell lipid peroxidation, plasma hemoglobin, and red blood cell osmotic resistance before and after vitamin E supplementation in hemodialysis patients. Artif Organs 10:245-250, 1986
61. SANAKA T, TAKAHASHI C, SANAKA M, et al: Accumulation of phosphatydilcholine-hydrogen peroxide in dialysis patients with diabetic nephropathy. Clin Nephrol 44:533-537, 1995
62. CRISTOL JP, BOSC JY, BADIOU S, et al: Erythropoietin and oxidative stress in haemodialysis: Beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 12:2312-2317, 1997
63. CHRISTEN S, WOODALL AA, SHIGENAGA MK, et al: Gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: Physiologic implications. Proc Natl Acad Sci 94:3217-3222, 1997
64. COONEY RV, FRANKE AA, HARWOOD PJ, et al: Gamma-tocopherol detoxification of nitrogen dioxide: Superiority to alpha-tocopherol. Proc Natl Acad Sci 90:1771-1775, 1993
65. DEVARAJ S, JIALAL I: Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Rad Biol Med 29:790-792, 2000